Today's top medical abstracts
Internal Med
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Internal Med
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Internal Med
        Academic Med/Education
        Adolescent Medicine
        Allergy/Immunology
        Atherosclerosis/Lipids
        Basic Science/Genetics
        Cardiology
        Clinical Pharmacology
        Complementary Medicine
        Critical Care/
    Hospitalist
        Dermatology
        Economics of Medicine
        Endocrinology
        Epidemiology
        Gastroenterology
        Geriatrics
        Hematology/Oncology
        Infectious Disease
        Nephrology/Urology
        Neurology
        Orthopedic/Physical Med
        Popular Press
        Preventive Medicine
        Primary Care
        Psychiatry
        Pulmonology
        Radiology/Diagnostics
        Rheumatology
        Sports Medicine
        Vascular Medicine
        Women`s Health
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
Cancer Science: #14. Does Size Matter? "Stumpy" Telomeres Allow Cancer Cells to Evade Senescence
Sara Hartley, MDLinx Oncology
  See all
Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis
American Heart Journal, 07/01/08
Print     Email This Article     Save in My Library   Free Abstract
Setoguchi S et al. – TNF-α antagonists (TNFAs) may increase the risk of both first hospitalization and exacerbation of heart failure (HF) in elderly patients with RA; larger and more detailed studies are needed to confirm the findings.

Methods
  • Aim was to determine if TNFAs pose an increased risk of HF in older pts with RA
  • Data from Medicare and drug benefit programs in 2 states
  • RA pts aged ≥65, who received TNFA or MTX
  • The cohort was divided into pts with and w/o previous HF
  • Demographic variables, cv risk factors, RA severity-related measures, and other comorbidities were considered
  • The primary end point was hospitalization with HF
  • Adjusted effect of TNFAs on HF hospitalization was estimated

Results
  • 1,002 TNFA users and 5,593 MTX users
  • 59 HF admissions during 1,680 person-years of TNFA use; 227 HF admissions during 10,623 person-years of MTX use
  • Adjusted hazard ratio for HF hospitalization was 1.70
  • Similar results were found in pts with and w/o previous HF
  • Among pts with previous HF, the adjusted hazard ratio for death was 4.19

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.